Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Endothelin Antagonists" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Endothelin antagonists
Owner:ABBVIE INC
Endothelin antagonists
InactiveUS7208517B1Suppression problemAvoid problemsBiocideAnimal repellantsLymphatic SpreadMedicine
A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.
Owner:ABBVIE INC
Use of endothelin antagonists to prevent restenosis
InactiveUS20050175667A1Improve efficiencyImprove efficacyBiocideOrganic active ingredientsPercent Diameter StenosisThrombus
Provided are devices and methods for treating or preventing smooth muscle cell proliferation caused by endothelin-mediated conditions. In particular, a medical device comprising a structure which is implantable within a body lumen and means on or within the structure for releasing an endothelin (A) receptor antagonist at a rate effective to inhibit smooth muscle cell proliferation. The device can be, for example, an expansible stent or a graft, and the means can include a matrix coating, wherein the endothelin (A) receptor antagonist can be dispersed within the coating or disposed directly on the structure and under the matrix. The methods and devices of this invention can be used to decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.
Owner:EDWARDS LIFESCIENCES LLC
Endothelin antagonists
Owner:ABBVIE INC
Method for screening for endothelin-receptor antagonist activity and for treating conditions caused by endothelin
InactiveUS20050008710A1Potent effectGood blood pressureBiocideCompound screeningFluorescenceEvaporation
Aliquots of extracts from ethnopharmacological plants that have activity against the effects of sarafotoxins present in snake venom are isolated and identified as antagonists of endothelin using a fluorescence-based assay. A process is provided for the identification of an antagonist of an endothelin selected from the group consisting of endothelin-1, endothelin-2, endothelin-3 and mixtures thereof. The process comprises extraction of ethnopharmacological plants with a solvent followed by evaporation of the solvent to form an aliquot containing at least one component of the extract, optionally purifying and isolating one or more component by chromatography, and subjecting the aliquot or purified component to a competitive fluorescent binding assay using biotinylated endothelin-1, wherein the plants having activity against the effects of one or more sarafotoxins present in snake venom.
Owner:PHYTOMYCO RES CORP
Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use
The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and / or heterocyclic nitric oxide donors.
Owner:NICOX SA
Whitening composition containing endothelin antagonist as well as preparation method and application thereof
InactiveCN110946796AInhibit transferAccelerates or inhibits metastasisCosmetic preparationsToilet preparationsPhospholipinPolyol
Owner:苏州绿叶日用品有限公司
Methods for reducing gnrh-positive tumor cell proliferation
InactiveUS20100190692A1Reduce time delayPromote formationCompounds screening/testingBiocideGerm layerNervous system
A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells originating in the brain and / or nervous system and / or the meninges and / or reactive neuroglia cells and / or primitive neuroectodermal tumor cells and / or on Kaposi sarcoma is provided. Furthermore a method for reducing degenerate GnRH-positive tumor cells and / or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and / or GnRH antagonist and / or an erythropoietin agonist, and / or a thrombopoietin agonist, and / or a endothelin antagonist and / or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.
Owner:VAN GROENINGHEN JOHANNES C
Composition for whitening and brightening skin and application of composition for whitening and brightening skin to cosmetics
The invention relates to a composition for whitening and brightening skin and an application of the composition for whitening and brightening skin to cosmetics. The composition comprises the followingcomponents of a glabridin carrier, hydroxyethylpiperazine ethane sulfonic acid (HEPES), an endothelin antagonist and plant composite essence. The composition for whitening and brightening skin can effectively restrain tyrosinase activity, restrain melanocyte disintegration, eliminate free radicals, soften cutin, improve skin withstanding capacity and the like; a glabridin carrier technique and plant fresh and living ingredients coexist, powerful efficacy of whitening skin and lightening freckles of the endothelin antagonist is used for cooperation, in the presence of the HEPES, synergistic interaction is achieved, and excellent efficacy of whitening skin and brightening skin can be achieved.
Owner:湖北省吉美化妆品有限公司
Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
The present invention relates, in general to treatment of pain comprising administering an alpha-2 adrenergic agonist and an endothelin antagonist, wherein administration of the agents acts as an analgesic and ameliorates pain in a subject.
Owner:ENDOGENX
Methods for reducing gnrh-positive tumor cell proliferation
InactiveUS20120238494A1Reduce time delayPromote formationBiocidePeptide/protein ingredientsGerm layerPresent method
A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and / or nervous system and / or the meninges and / or reactive neuroglia cells and / or primitive neuroectodermal tumor cells and / or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and / or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and / or GnRH antagonist and / or an erythropoietin agonist, and / or a thrombopoietin agonist, and / or a endothelin antagonist and / or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.
Owner:VAN GROENINGHEN JOHANNES C
Skin whitening and freckle removing composition and application thereof
InactiveCN109431844AGood active ingredientMitogenic activityCosmetic preparationsToilet preparationsWrinkle skinSunscreen agents
The invention discloses skin whitening and freckle removing composition and an application thereof. The composition comprises forchlorfenuron and a whitening agent, wherein the whitening agent adoptsa tyrosinase activity inhibitor, a tyrosinase saccharification inhibitor, a tyrosinase decomposition agent, a melanocyte toxicity agent, a melanin transport blocking agent, a sunscreen agent, a reducing agent, a chemical stripping agent and an endothelin antagonist or a free radical scavenger. The composition can remove wrinkles and freckles, prevent water loss and keep skin moist, and has the functions of whitening the skin, removing freckles and wrinkles, preserving moisture and the like. Compared with the prior art, the composition is safe to use, simple and convenient to manufacture and suitable for industrial mass production.
Owner:ZHEJIANG TIDE CROP TECH
Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist
InactiveUS20110263542A1Good analgesic effectProduce analgesiaBiocideNervous disorderEndothelin receptor antagonistEndothelin Antagonists
The present invention relates, in general to treatment of pain comprising administering an alpha-2 adrenergic agonist and an endothelin antagonist, wherein administration of the agents acts as an analgesic and ameliorates pain in a subject.
Owner:ENDOGENX
Method and composition for treating diabetic ketoacidosis
InactiveUS8980874B2Reduce complicationsReduce occurrenceBiocidePeptide/protein ingredientsDiabetic ketoacidosisEndothelin Antagonists
Owner:MID WESTERN UNIVERSITY BIRENDRANAGAR
Fat-soluble glabridin compound whitening agent and application thereof
ActiveCN108498412ASimple recipeGood whitening effectCosmetic preparationsToilet preparationsQuinoneWhitening Agents
The invention discloses a fat-soluble glabridin compound whitening agent and application of the agent in cosmetics. The compound whitening agent is prepared from the following active ingredients in byweight percent: 30-50 percent of glycyrrhiza glabra extract, 10-30 percent of tetrahydroxychalcone, 10-30 percent of ubiquinone and 10-30 percent of an endothelin antagonist. The compound whitening agent has main whitening action mechanisms of inhibiting the activity of tyrosinase, inhibiting the activity of DOPA chrome tautomerase and obstructing indole-5,6-quinone polymerization, so that melanogenesis can be obstructed, differentiation of melanophores can be reduced, and the aims of whitening skin, lightening spots and improving dark skin color can be achieved. The compound whitening agenthas a simple and practical formula and a good whitening and spot-lightening effect, is environmentally friendly and safe since natural products are adopted, is mild and nonirritant in use, and can overcome the defect in an existing whitening agent.
Owner:亿利耐雀生物科技有限公司
Blood vessel ice-crystal-free cryopreservation solution and blood vessel preservation method
ActiveCN111264516AImprove the preservation effectImprove long-term patencyCulture processArtificial cell constructsPyrrolidinonesBlood vessel
The invention discloses a blood vessel ice-crystal-free cryopreservation solution and a blood vessel preservation method. The blood vessel ice-crystal-free cryopreservation solution comprises 1.0-6.0mol / L of glycerol, 1.0-7.0 mol / L of formamide, 0.1-2.5 mol / L of polyvinylpyrrolidone and a component X; wherein the component X is one or more of a component A, a component B and a component C; wherein the component A is an NO donor, the component B is an endothelin inhibitor or an endothelin antagonist, and the component C is an anti-apoptotic agent. According to the preserving fluid disclosed bythe invention, the preserving effect on the vascular function is improved, especially for vascular smooth muscle cells and endothelial cells which are most easily subjected to cryopreservation injury; the vascular smooth muscle cell and the endothelial cell can be effectively protected, the function of effectively protecting the vascular smooth muscle cell and the endothelial cell is achieved; inaddition, the long-term patency rate after vascular transplantation is increased, and the success rate of clinical vascular transplantation is greatly guaranteed.
Owner:江苏科瑞百奥生物技术有限公司
Pyridine ring-substituted alpha-hydroxycarboxylic acid derivatives, preparation method thereof and use thereof
The invention relates to the fields of medicaments for treating blood pressure diseases and particularly relates to pyridine ring-substituted alpha-hydroxycarboxylic acid derivatives of a general formula I, preparation method thereof, medicinal compositions having the same and use thereof as an endothelin antagonist in the preparation of medicaments for treating hypertension and pulmonary hypertension, wherein groups are defined in the description.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Moisturizing and skin-moistening sunscreen cream
InactiveCN106109292ALock in moistureGood sun protectionCosmetic preparationsToilet preparationsWrinkle skinTetrandrine
The invention discloses a water-replenishing and moisturizing sunscreen, which is made of the following raw materials in parts by mass: 7-9 parts of glycerin stearate, 6-10 parts of shea butter, and 3-parts of polydimethylsiloxane 6 parts, 6‑8 parts of active raspberry polyphenols, 5‑7 parts of olive oil, 6‑9 parts of tetrandrine, 7‑11 parts of chitin, 5‑7 parts of menthol, 3‑5 parts of dihydroxyacetone, 8‑12 parts of polyoxyethylene sorbitan monostearate, 6‑10 parts of titanium dioxide, 4‑8 parts of aloe extract, 11‑14 parts of zinc oxide particles, 6‑7 parts of collagen, endothelin antagonist 4‑5 parts, 5‑7 parts of cinnamic acid, 6‑9 parts of isopropyl palmitate, 7‑9 parts of lanolin, and the rest is water. The invention has good sun protection effect, can lock the moisture on the skin, can moisturize and maintain the skin, and prevents aging, wrinkles and stains.
Owner:青岛艾派克生物科技有限公司
Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
InactiveUS20040127884A1Limit their usefulnessLow costTripeptide ingredientsMedical devicesProtein-Tyrosine KinasesPercent Diameter Stenosis
A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. The solution is introduced luminally to continuously irrigate an arterial site during an operative / interventional or diagnostic procedure for preemptive inhibition of pain and inflammation, vascular and non-vascular smooth muscle spasm, and restenosis while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain, inflammation, vasospasm and restenosis includes a serotonin2 antagonist, a cyclooxygenase inhibitor, an endothelin antagonist, an ATP-sensitive K<+> channel antagonist, a Ca<2+> channel antagonist, a nitric oxide donor, an anti-thrombin agent, a glycoprotein IIb / IIIa receptor blocker, a PKC inhibitor and a protein tyrosine kinase inhibitor.
Owner:OMEROS CORP
Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
InactiveUS8962558B2Reduce time delayPromote formationBiocideOrganic active ingredientsNervous systemPresent method
Owner:VAN GROENINGHEN JOHANNES C
Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic
InactiveUS20080207763A1Affect propertyImprove heat dissipation abilityBiocideSalicyclic acid active ingredientsActive agentTreatment fever
Owner:UNIV OF ILLINOIS CHICAGO
Pearl shell whitening factor, and preparation method and application thereof
PendingCN111850073AShort preparation timeSave timeCosmetic preparationsToilet preparationsFreeze-dryingChemical engineering
The invention discloses a preparation method for a pearl shell whitening factor. The preparation method comprises the following steps: 1) crushing clamshells, and conducting screening to obtain small-particle clamshell powder; 2) mixing the clamshell powder with an aqueous weak acid solution, conducting stirring and decomposing, and separating out a solid, namely crude protein; 3) cleaning the crude protein with deionized water, mixing the cleaned crude protein with a buffer solution having a pH value of 6.0-7.5, treating the mixed solution for 20-40 minutes at an ultrahigh pressure of 100-200Mpa and a temperature of 40-80 DEG C, and subjecting the mixed solution and protease to mixing and reacting for 2-7 hours at a temperature of 40-60 DEG C under ultrasonic conditions; 4) carrying outstirring for 20-50 minutes at 85-100 DEG C for enzyme deactivation, and performing filter pressing through a filter membrane to obtain a sterile filtrate; 5) mixing a freeze-drying protective agent with the filtrate, conducting pre-freezing, and then performing freeze-drying in a vacuum freeze-drying bin for 12-20 hours so as to finally obtain freeze-dried powder with a moisture content of 2-5%. The invention also discloses application of the pearl shell whitening factor obtained by the method in preparation of an endothelin antagonist. The preparation method is simple in process, and the obtained pearl shell whitening factor is obvious in whitening effect.
Owner:OSMUN BIOLOGICAL
Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
InactiveUS20070238740A1Improve propertiesBiocideSenses disorderRenovascular diseaseAngiotensin ii antagonist
Owner:NICOX SA
Skin care wet tissue additive solution with whitening and moistening functions
InactiveCN104352404ANo irritationNo side effectsCosmetic preparationsToilet preparationsSide effectMagnesium phosphate
The invention discloses a skin care wet tissue additive solution with whitening and moistening functions and relates to the technical field of skin care wet tissue production. The skin care wet tissue additive solution is prepared from the following raw materials in percentage by mass: 25-35% of a raspberry fruit extract, 15-30% of a felwort extract, 10-20% of a lemon extract, 10-15% of a radix puerariae extract, 5-10% of a radix angelicae extract, 5-8% of arbutin, 5-7% of kojic acid, 3-6% of an endothelin antagonist, 3-6% of ascorbic acid magnesium phosphate, 3-5% of almond powder, 2.5-4.5% of pearl powder, 2-4% of pineapple ferment, 1.5-3% of papaya enzyme, 2-3.5% of hydrolate, 1.5-2.5% of linoleic acid and 0.3-0.5% of a preservative. The wet tissue additive solution prepared by using natural plant ingredients as the main raw materials is mild to the skin, has no irritation or side effect and can be well absorbed by the skin. Meanwhile, the wet tissue additive solution has the double functions of whitening and moistening and fully nourishes the skin.
Owner:铜陵麟安生物科技股份有限公司
Moisturizing sun cream
InactiveCN103655272AWith UV protectionEmollientCosmetic preparationsToilet preparationsIsononyl IsononanoateStearic acid
The invention discloses a moisturizing sun cream. The moisturizing sun cream is prepared from the raw materials in parts by weight: 2-6 parts of dioxyacetone, 3-6 parts of polyoxyethylene 20 sorbitan monostearate, 4-12 parts of ultrafine titanium dioxide, 2-5 parts of stearic acid, 10-20 parts of aloe powder, 3-6 parts of endothelin antagonists, 4-8 parts of cinnamic acid, 10-20 parts of octyl salicylate, 15-25 parts of hydroxyethyl cellulose, 8-16 parts of isononyl isononanoate, 7-14 parts of cyclomethicone, 6-12 parts of cetyl dimethicone, 3-9 parts of glycerin monostearate, 2-4 parts of triethanolamine and 20-50 parts of deionized water. The invention provides the moisturizing sun cream which has the function of preventing ultraviolet rays and sunshine and also has the actions of skin moistening, moisturizing, skin injury repairing and skin moisture replenishing.
Owner:QINGDAO CHENXUTONG COMMERCE & TRADE
Skin care spray with skin-whitening, spot-fading, and acne-removing functions and preparation method thereof
InactiveCN108815095ANon-irritatingNo side effectsCosmetic preparationsToilet preparationsVitamin CMedicine
The invention provides a skin care spray with skin-whitening, spot-fading, and acne-removing functions. The skin care spray is mainly composed of following components in percentage by weight: 2 to 6%of vitamin C, 5 to 8% of pearl powder, 4 to 10% of plant extract, 10 to 30% of aloe, 3 to 10% of endothelin antagonist, 0.05 to 2% of hyaluronic acid, 0.5 to 1.5% of salicylic acid, 5 to 10% of lavender essential oil, 20 to 35% of deionized water, and 20 to 30% of skincare product auxiliary matrix. The skin care spray is mild and nonirritant, is suitable for various skins, has skin-whitening, spot-fading, and acne-removing functions, and makes skin become smooth, lustrous and elastic for a long term.
Owner:WUHU LINGMENG E COMMERCE CO LTD
Phenoxy phenylacetic acid endothelin antagonist, and preparation method and application thereof
ActiveCN103539760AStrong endothelin receptor antagonist activityOrganic chemistryMetabolism disorderNephrosisDisease
The invention provides a phenoxy phenylacetic acid endothelin antagonist shown in a formula (I) or a pharmaceutically acceptable salt thereof, and also provides a preparation method of the benzene oxygen phenylacetic acid endothelin antagonist or the pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medicament for treating cardiovascular and cerebrovascular diseases, tumors, diabetes mellitus, nephrosis, asthma or hyperthyroidism.
Owner:SOUTHEAST UNIV
Endothelin antagonist and beta receptor blocking agent as comblined preparation
InactiveCN1149087CBlood pressure did not dropLower blood pressureOrganic active ingredientsUrinary disorderDiseaseEndothelin Antagonists
The invention relates to a combination consisting of endothelin-antagonists and beta receptor blocking agents. Said combination is suitable for the treatment of diseases.
Owner:ABBVIE DEUTSHLAND GMBH & CO KG
Medical biological face cream with effects of whitening and removing freckles and preparation method of face cream
InactiveCN107773525APromote growthDilute epidermal pigmentCosmetic preparationsToilet preparationsWrinkle skinCuticle
Owner:济源市王屋山实业有限公司
Methods of treating vascular diseases characterized by nitric oxide insufficiency
The invention provides methods of treating and / or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and / or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and / or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and / or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.
Owner:NITROMED
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com